
Understanding ESR1 Mutations in Breast Cancer
Metastatic breast cancer treatments face new complexities with the advent of ESR1 mutations, especially in hormone receptor-positive, HER2-negative cases. ESR1 mutations drive endocrine resistance and tumor growth, posing challenges after CDK4/6 inhibitor use. With emerging therapies like selective estrogen receptor degraders and advancing diagnostic methods, managing ESR1 mutations offers hope for improved patient outcomes. A […]
3 minute read